ClinicalTrials.gg
RecruitingNCT05747144MICAIUpdated Feb 13, 2024

Multimodal Imaging in Vitreo-retinal Surgery and Macular Dystrophies

An observational study in Macular Holes, Epiretinal Membrane and Retinal Detachment, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Months and older
Sex
All
01

Study summary

The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery, using decisional support systems (DSS), based on multimodal big-data analysis by means of machine learning techniques in daily clinical practice

Read the detailed description

The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery. Identifying the biomarkers and assessing the predictivity of recovery will make it possible to highlight the categories of patients who can benefit most from surgical treatment, and to target the patient more precisely for personalised medicine and surgery. The introduction of new decisional support systems (DSS), based on multimodal big-data analysis through machine learning techniques in daily clinical practice, is providing new useful information in patient assessment for personalised surgery.

02

Conditions studied

  • Macular Holes
  • Epiretinal Membrane
  • Retinal Detachment
  • Macular Dystrophies

Keywords

  • vitreoretinal surgery
  • machine learning
  • decisional support systems
03

In context

Retinal Perforations

139 studies on the registry are indexed under Retinal Perforations; 22 are open to participants now.

This study's planned enrollment of 100 is above the median of 50 across 43 observational studies indexed under Retinal Perforations.

Browse Retinal Perforations studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients to undergo vitreo-retinal surgery for macular disease (i.e.Macular hole, epiretinal membranes, Retinal detachment, Macular dystrophies (retinal pre-prosthesis).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients to undergo vitreo-retinal surgery for:

    1. Macular hole
    2. Epiretinal membranes
    3. Retinal detachment
    4. Macular dystrophies (retinal pre-prosthesis)

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age will be excluded; patients in whom morphological examinations cannot be performed due to poor cooperation or opacity of the dioptric media (e.g. corneal pathology). Quality of morphological images inadequate for post acquisition processing (\<6/10).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Macular hole

    Patients affected by macular hole.

    Diagnostic Test: Biometry · Diagnostic Test: Retinography (Color) + Autofluorescence (AF) · Diagnostic Test: OCT B-scan and OCT angiography (OCTA) · Diagnostic Test: Microperimetry · Diagnostic Test: Electrophysiological exams

  • Epiretinal membranes

    Patients affected by epiretinal membrane.

    Diagnostic Test: Biometry · Diagnostic Test: Retinography (Color) + Autofluorescence (AF) · Diagnostic Test: OCT B-scan and OCT angiography (OCTA) · Diagnostic Test: Microperimetry · Diagnostic Test: Electrophysiological exams

  • Retinal detachment

    Patients affected by retinal detachment.

    Diagnostic Test: Biometry · Diagnostic Test: Retinography (Color) + Autofluorescence (AF) · Diagnostic Test: OCT B-scan and OCT angiography (OCTA) · Diagnostic Test: Microperimetry · Diagnostic Test: Electrophysiological exams

  • Macular dystrophies

    Patients affected by macular dystrophies.

    Diagnostic Test: Biometry · Diagnostic Test: Retinography (Color) + Autofluorescence (AF) · Diagnostic Test: OCT B-scan and OCT angiography (OCTA) · Diagnostic Test: Microperimetry · Diagnostic Test: Electrophysiological exams

Interventions

  • Diagnostic testBiometry

    Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed

  • Diagnostic testRetinography (Color) + Autofluorescence (AF)

    Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)

  • Diagnostic testOCT B-scan and OCT angiography (OCTA)

    OCT B-scan: 2 scans (6 mm) 1 cross line OCTA: 3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve

  • Diagnostic testMicroperimetry

    1) fixation pattern 2) retinal sensitivity map

  • Diagnostic testElectrophysiological exams

    Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus \< 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.

06

What researchers measure

Primary outcomes

  1. Predictivity of morphological-functional radiomic data

    Rate of predictivity of morphological-functional radiomic data to establish the grade of recovery in the post-operative period by means of an artificial intelligence (AI) machine learning model.

    Time frame: 3 years

Secondary outcomes

  1. Identify predictive differences according to diagnosis

    Subdivision into subgroups in order to identify predictive differences according to diagnosis

    Time frame: 3 years

  2. Correlating with the age of patients

    Identify predictive differences according to diagnosis and correlate them with the age of patients

    Time frame: 3 years

  3. Correlate with age of onset of disease

    Identify predictive differences according to diagnosis and correlate them with the age of onset of disease

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Garrity ST, Sarraf D, Freund KB, Sadda SR. Multimodal Imaging of Nonneovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD48-AMD64. doi: 10.1167/iovs.18-24158. PubMed 30025107 ↗
  • Acon D, Wu L. Multimodal Imaging in Diabetic Macular Edema. Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):22-27. doi: 10.22608/APO.2017504. Epub 2017 Jan 29. PubMed 29376234 ↗
  • Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013 Dec;120(12):2611-2619. doi: 10.1016/j.ophtha.2013.07.042. Epub 2013 Sep 17. PubMed 24053995 ↗
  • Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018 May;64:1-55. doi: 10.1016/j.preteyeres.2017.11.003. Epub 2017 Dec 8. PubMed 29229445 ↗
  • Sun P, Tandias RM, Yu G, Arroyo JG. SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND VISUAL OUTCOME AFTER TREATMENT FOR VITREOMACULAR TRACTION. Retina. 2019 Jun;39(6):1054-1060. doi: 10.1097/IAE.0000000000002116. PubMed 29595569 ↗
  • Lee CS, Tyring AJ, Deruyter NP, Wu Y, Rokem A, Lee AY. Deep-learning based, automated segmentation of macular edema in optical coherence tomography. Biomed Opt Express. 2017 Jun 23;8(7):3440-3448. doi: 10.1364/BOE.8.003440. eCollection 2017 Jul 1. PubMed 28717579 ↗
  • Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A; International Retina Group. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2018 Feb;125(2):267-275. doi: 10.1016/j.ophtha.2017.08.031. Epub 2017 Sep 19. PubMed 28935399 ↗
  • Beam AL, Kohane IS. Big Data and Machine Learning in Health Care. JAMA. 2018 Apr 3;319(13):1317-1318. doi: 10.1001/jama.2017.18391. No abstract available. PubMed 29532063 ↗
  • Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. Lancet Oncol. 2019 May;20(5):e262-e273. doi: 10.1016/S1470-2045(19)30149-4. Erratum In: Lancet Oncol. 2019 Jun;20(6):293. doi: 10.1016/S1470-2045(19)30294-3. PubMed 31044724 ↗
  • Abramoff MD, Lou Y, Erginay A, Clarida W, Amelon R, Folk JC, Niemeijer M. Improved Automated Detection of Diabetic Retinopathy on a Publicly Available Dataset Through Integration of Deep Learning. Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5200-5206. doi: 10.1167/iovs.16-19964. PubMed 27701631 ↗
  • Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, Venugopalan S, Widner K, Madams T, Cuadros J, Kim R, Raman R, Nelson PC, Mega JL, Webster DR. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA. 2016 Dec 13;316(22):2402-2410. doi: 10.1001/jama.2016.17216. PubMed 27898976 ↗
  • Lakhani P, Sundaram B. Deep Learning at Chest Radiography: Automated Classification of Pulmonary Tuberculosis by Using Convolutional Neural Networks. Radiology. 2017 Aug;284(2):574-582. doi: 10.1148/radiol.2017162326. Epub 2017 Apr 24. PubMed 28436741 ↗
  • Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017 Feb 2;542(7639):115-118. doi: 10.1038/nature21056. Epub 2017 Jan 25. Erratum In: Nature. 2017 Jun 28;546(7660):686. doi: 10.1038/nature22985. PubMed 28117445 ↗
  • Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, Hamzah H, Garcia-Franco R, San Yeo IY, Lee SY, Wong EYM, Sabanayagam C, Baskaran M, Ibrahim F, Tan NC, Finkelstein EA, Lamoureux EL, Wong IY, Bressler NM, Sivaprasad S, Varma R, Jonas JB, He MG, Cheng CY, Cheung GCM, Aung T, Hsu W, Lee ML, Wong TY. Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. JAMA. 2017 Dec 12;318(22):2211-2223. doi: 10.1001/jama.2017.18152. PubMed 29234807 ↗
  • Li Z, He Y, Keel S, Meng W, Chang RT, He M. Efficacy of a Deep Learning System for Detecting Glaucomatous Optic Neuropathy Based on Color Fundus Photographs. Ophthalmology. 2018 Aug;125(8):1199-1206. doi: 10.1016/j.ophtha.2018.01.023. Epub 2018 Mar 2. PubMed 29506863 ↗
  • Burlina P, Joshi N, Pacheco KD, Freund DE, Kong J, Bressler NM. Utility of Deep Learning Methods for Referability Classification of Age-Related Macular Degeneration. JAMA Ophthalmol. 2018 Nov 1;136(11):1305-1307. doi: 10.1001/jamaophthalmol.2018.3799. PubMed 30193354 ↗
  • Grassmann F, Mengelkamp J, Brandl C, Harsch S, Zimmermann ME, Linkohr B, Peters A, Heid IM, Palm C, Weber BHF. A Deep Learning Algorithm for Prediction of Age-Related Eye Disease Study Severity Scale for Age-Related Macular Degeneration from Color Fundus Photography. Ophthalmology. 2018 Sep;125(9):1410-1420. doi: 10.1016/j.ophtha.2018.02.037. Epub 2018 Apr 10. PubMed 29653860 ↗
  • Brown JM, Campbell JP, Beers A, Chang K, Ostmo S, Chan RVP, Dy J, Erdogmus D, Ioannidis S, Kalpathy-Cramer J, Chiang MF; Imaging and Informatics in Retinopathy of Prematurity (i-ROP) Research Consortium. Automated Diagnosis of Plus Disease in Retinopathy of Prematurity Using Deep Convolutional Neural Networks. JAMA Ophthalmol. 2018 Jul 1;136(7):803-810. doi: 10.1001/jamaophthalmol.2018.1934. PubMed 29801159 ↗
  • Kermany DS, Goldbaum M, Cai W, Valentim CCS, Liang H, Baxter SL, McKeown A, Yang G, Wu X, Yan F, Dong J, Prasadha MK, Pei J, Ting MYL, Zhu J, Li C, Hewett S, Dong J, Ziyar I, Shi A, Zhang R, Zheng L, Hou R, Shi W, Fu X, Duan Y, Huu VAN, Wen C, Zhang ED, Zhang CL, Li O, Wang X, Singer MA, Sun X, Xu J, Tafreshi A, Lewis MA, Xia H, Zhang K. Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning. Cell. 2018 Feb 22;172(5):1122-1131.e9. doi: 10.1016/j.cell.2018.02.010. PubMed 29474911 ↗
  • De Fauw J, Ledsam JR, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, Askham H, Glorot X, O'Donoghue B, Visentin D, van den Driessche G, Lakshminarayanan B, Meyer C, Mackinder F, Bouton S, Ayoub K, Chopra R, King D, Karthikesalingam A, Hughes CO, Raine R, Hughes J, Sim DA, Egan C, Tufail A, Montgomery H, Hassabis D, Rees G, Back T, Khaw PT, Suleyman M, Cornebise J, Keane PA, Ronneberger O. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018 Sep;24(9):1342-1350. doi: 10.1038/s41591-018-0107-6. Epub 2018 Aug 13. PubMed 30104768 ↗
  • Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunovic H. Artificial intelligence in retina. Prog Retin Eye Res. 2018 Nov;67:1-29. doi: 10.1016/j.preteyeres.2018.07.004. Epub 2018 Aug 1. PubMed 30076935 ↗
  • Schmidt-Erfurth U, Waldstein SM, Klimscha S, Sadeghipour A, Hu X, Gerendas BS, Osborne A, Bogunovic H. Prediction of Individual Disease Conversion in Early AMD Using Artificial Intelligence. Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3199-3208. doi: 10.1167/iovs.18-24106. PubMed 29971444 ↗
  • Sarao V, Veritti D, Borrelli E, Sadda SVR, Poletti E, Lanzetta P. A comparison between a white LED confocal imaging system and a conventional flash fundus camera using chromaticity analysis. BMC Ophthalmol. 2019 Nov 19;19(1):231. doi: 10.1186/s12886-019-1241-8. PubMed 31744471 ↗
  • Fernandez-Avellaneda P, Breazzano MP, Fragiotta S, Xu X, Zhang Q, Wang RK, Freund KB. BACILLARY LAYER DETACHMENT OVERLYING REDUCED CHORIOCAPILLARIS FLOW IN ACUTE IDIOPATHIC MACULOPATHY. Retin Cases Brief Rep. 2022 Jan 1;16(1):59-66. doi: 10.1097/ICB.0000000000000943. PubMed 31764886 ↗
  • Huang NT, Georgiadis C, Gomez J, Tang PH, Drayna P, Koozekanani DD, van Kuijk FJGM, Montezuma SR. Comparing fundus autofluorescence and infrared imaging findings of peripheral retinoschisis, schisis detachment, and retinal detachment. Am J Ophthalmol Case Rep. 2020 Mar 26;18:100666. doi: 10.1016/j.ajoc.2020.100666. eCollection 2020 Jun. PubMed 32258825 ↗
  • Stanga PE, Williams JI, Shaarawy SA, Agarwal A, Venkataraman A, Kumar DA, You TT, Hope RS. FIRST-IN-HUMAN CLINICAL STUDY TO INVESTIGATE THE EFFECTIVENESS AND SAFETY OF PARS PLANA VITRECTOMY SURGERY USING A NEW HYPERSONIC TECHNOLOGY. Retina. 2020 Jan;40(1):16-23. doi: 10.1097/IAE.0000000000002365. PubMed 30358763 ↗
  • Hubschman JP, Govetto A, Spaide RF, Schumann R, Steel D, Figueroa MS, Sebag J, Gaudric A, Staurenghi G, Haritoglou C, Kadonosono K, Thompson JT, Chang S, Bottoni F, Tadayoni R. Optical coherence tomography-based consensus definition for lamellar macular hole. Br J Ophthalmol. 2020 Dec;104(12):1741-1747. doi: 10.1136/bjophthalmol-2019-315432. Epub 2020 Feb 27. PubMed 32107208 ↗
  • Bae K, Lee SM, Kang SW, Kim ES, Yu SY, Kim KT. Atypical epiretinal tissue in full-thickness macular holes: pathogenic and prognostic significance. Br J Ophthalmol. 2019 Feb;103(2):251-256. doi: 10.1136/bjophthalmol-2017-311810. Epub 2018 Apr 26. PubMed 29699982 ↗
  • Rizzo S, Tartaro R, Barca F, Caporossi T, Bacherini D, Giansanti F. INTERNAL LIMITING MEMBRANE PEELING VERSUS INVERTED FLAP TECHNIQUE FOR TREATMENT OF FULL-THICKNESS MACULAR HOLES: A COMPARATIVE STUDY IN A LARGE SERIES OF PATIENTS. Retina. 2018 Sep;38 Suppl 1:S73-S78. doi: 10.1097/IAE.0000000000001985. PubMed 29232338 ↗
  • Christensen UC. Value of internal limiting membrane peeling in surgery for idiopathic macular hole and the correlation between function and retinal morphology. Acta Ophthalmol. 2009 Dec;87 Thesis 2:1-23. doi: 10.1111/j.1755-3768.2009.01777.x. PubMed 19912135 ↗
  • Fukuyama H, Ishikawa H, Komuku Y, Araki T, Kimura N, Gomi F. Comparative analysis of metamorphopsia and aniseikonia after vitrectomy for epiretinal membrane, macular hole, or rhegmatogenous retinal detachment. PLoS One. 2020 May 8;15(5):e0232758. doi: 10.1371/journal.pone.0232758. eCollection 2020. PubMed 32384099 ↗
  • Rizzo S, Savastano A, Bacherini D, Savastano MC. Vascular Features of Full-Thickness Macular Hole by OCT Angiography. Ophthalmic Surg Lasers Imaging Retina. 2017 Jan 1;48(1):62-68. doi: 10.3928/23258160-20161219-09. PubMed 28060396 ↗
  • Bacherini D, Savastano MC, Dragotto F, Finocchio L, Lenzetti C, Bitossi A, Tartaro R, Giansanti F, Barca F, Savastano A, Caporossi T, Vannozzi L, Sodi A, Luca M, Faraldi F, Virgili G, Rizzo S. Morpho-Functional Evaluation of Full-Thickness Macular Holes by the Integration of Optical Coherence Tomography Angiography and Microperimetry. J Clin Med. 2020 Jan 15;9(1):229. doi: 10.3390/jcm9010229. PubMed 31952306 ↗
  • Qi Y, Wang Z, Li SM, You Q, Liang X, Yu Y, Liu W. Effect of internal limiting membrane peeling on normal retinal function evaluated by microperimetry-3. BMC Ophthalmol. 2020 Apr 9;20(1):140. doi: 10.1186/s12886-020-01383-3. PubMed 32272972 ↗
  • Smith AJ, Telander DG, Zawadzki RJ, Choi SS, Morse LS, Werner JS, Park SS. High-resolution Fourier-domain optical coherence tomography and microperimetric findings after macula-off retinal detachment repair. Ophthalmology. 2008 Nov;115(11):1923-9. doi: 10.1016/j.ophtha.2008.05.025. Epub 2008 Jul 31. PubMed 18672289 ↗
  • Reumueller A, Wassermann L, Salas M, Karantonis MG, Sacu S, Georgopoulos M, Drexler W, Pircher M, Pollreisz A, Schmidt-Erfurth U. Morphologic and Functional Assessment of Photoreceptors After Macula-Off Retinal Detachment With Adaptive-Optics OCT and Microperimetry. Am J Ophthalmol. 2020 Jun;214:72-85. doi: 10.1016/j.ajo.2019.12.015. Epub 2019 Dec 25. PubMed 31883465 ↗
  • Falsini B, Serrao S, Fadda A, Iarossi G, Porrello G, Cocco F, Merendino E. Focal electroretinograms and fundus appearance in nonexudative age-related macular degeneration. Quantitative relationship between retinal morphology and function. Graefes Arch Clin Exp Ophthalmol. 1999 Mar;237(3):193-200. doi: 10.1007/s004170050218. PubMed 10090581 ↗
  • Falsini B, Bardocci A, Porciatti V, Bolzani R, Piccardi M. Macular dysfunction in multiple sclerosis revealed by steady-state flicker and pattern ERGs. Electroencephalogr Clin Neurophysiol. 1992 Jan;82(1):53-9. doi: 10.1016/0013-4694(92)90182-h. PubMed 1370144 ↗
  • Abed E, Placidi G, Campagna F, Federici M, Minnella A, Guerri G, Bertelli M, Piccardi M, Galli-Resta L, Falsini B. Early impairment of the full-field photopic negative response in patients with Stargardt disease and pathogenic variants of the ABCA4 gene. Clin Exp Ophthalmol. 2018 Jul;46(5):519-530. doi: 10.1111/ceo.13115. Epub 2017 Dec 28. PubMed 29178665 ↗
  • Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9. PubMed 31078660 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jan 2025, 48 months after the start.

Of 16 observational studies under Retinal Perforations, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 144. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Feb 28, 2023
StartActual
Jan 15, 2021
Primary completionEst.
Jan 15, 2025
CompletionEst.
Jan 16, 2025
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05747144
Responsible party
RIZZO STANISLAO (Professor, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Feb 28, 2023
Start date
Jan 15, 2021
Primary completion
Jan 15, 2025 (estimated)
Completion
Jan 16, 2025 (estimated)
Last update
Feb 13, 2024

Study contacts

Maria Cristina Savastano, MD,PhD
Contact
mariacristina.savastano@unicatt.it
+39 3384443002
Alfonso Savastano, MD,PhD
Contact
alfonso.savastano@policlinicogemelli.it

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion